Puma Biotechnology, Inc. (PBYI)

NASDAQ: PBYI · Real-Time Price · USD
3.160
-0.110 (-3.36%)
At close: Dec 4, 2024, 4:00 PM
3.209
+0.049 (1.56%)
After-hours: Dec 4, 2024, 6:42 PM EST
-3.36%
Market Cap 155.12M
Revenue (ttm) 243.57M
Net Income (ttm) 23.24M
Shares Out 49.09M
EPS (ttm) 0.47
PE Ratio 6.79
Forward PE 9.58
Dividend n/a
Ex-Dividend Date n/a
Volume 396,261
Open 3.280
Previous Close 3.270
Day's Range 3.140 - 3.292
52-Week Range 2.230 - 7.730
Beta 1.08
Analysts Strong Buy
Price Target 7.00 (+121.52%)
Earnings Date Nov 7, 2024

About PBYI

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breas... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 185
Stock Exchange NASDAQ
Ticker Symbol PBYI
Full Company Profile

Financial Performance

In 2023, Puma Biotechnology's revenue was $235.64 million, an increase of 3.34% compared to the previous year's $228.03 million. Earnings were $21.59 million, an increase of 1079450.00%.

Financial Statements

Analyst Forecast

According to one analyst, the rating for PBYI stock is "Strong Buy" and the 12-month stock price forecast is $7.0.

Price Target
$7.0
(121.52% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Puma Biotechnology Announces Initiation of ALISCA™-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology has initiated a clinical trial of alisertib with endocrine therapy in patients with HR+ HER2-negative metastatic breast cancer.

14 days ago - Business Wire

Puma Biotechnology, Inc. (PBYI) Q3 2024 Earnings Conference Call Transcript

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, IR Alan Auerbach - CEO, President and Cha...

26 days ago - Seeking Alpha

Puma Biotechnology Reports Third Quarter 2024 Financial Results

LOS ANGELES--(BUSINESS WIRE)--On Nov. 7, Puma Biotechnology issued its earnings results for 3Q-2024 and hosted a conference call to discuss the details.

27 days ago - Business Wire

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on November 4, 2024, the Compensation Committee of Puma's Board of Directors approved...

4 weeks ago - Business Wire

Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue its 3Q-2024 results after markets close on Nov. 7 and host a conference call to discuss results at 1:30 pm PT.

5 weeks ago - Business Wire

Puma Biotechnology to Present at the H.C. Wainwright 26th Annual Global Investment Conference

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO and President of Puma Biotechnology, will present a company overview on Sept. 9 at H.C. Wainwright's 26th Annual Global Inv. Conf.

3 months ago - Business Wire

Puma Biotechnology, Inc. (PBYI) Q2 2024 Earnings Call Transcript

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q2 2024 Earnings Call August 1, 2024 4:30 PM ET Company Participants Mariann Ohanesian - Senior Director, Investor Relations Alan Auerbach - Chief Executive Off...

4 months ago - Seeking Alpha

Puma Biotechnology Reports Second Quarter Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology issued its second quarter financial results and hosted a conference call on August 1, 2024.

4 months ago - Business Wire

Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2024 Financial Results

LOS ANGELES--(BUSINESS WIRE)--On Aug. 1, Puma Biotechnology will issue its earnings results for the 2024 second quarter and follow with a conference call to discuss the results.

4 months ago - Business Wire

Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology Announced Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung Cancer at the 2024 ASCO Annual Meeting.

6 months ago - Business Wire

Puma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that findings from the Phase II trial of its drug alisertib (TBCRC 041) were presented at the ASCO 2024 Annual Meeting.

6 months ago - Business Wire

Puma Biotechnology to Join Russell 3000 Index

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology is on the preliminary list of additions to the Russell 3000 Index.

6 months ago - Business Wire

Puma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual Meeting

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that two abstracts for its drug Alisertib to be presented at the 2024 ASCO Annual Meeting are now posted on ASCO.org.

6 months ago - Business Wire

Puma Biotechnology, Inc. (PBYI) Q1 2024 Earnings Call Transcript

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2024 Earnings Conference Call May 2, 2024 4:30 PM ET Company Participants Mariann Ohanesian – Senior Director-Investor Relations Alan Auerbach – Chief Execut...

7 months ago - Seeking Alpha

Puma Biotechnology Reports First Quarter Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will report its financial results for 1Q-2024 after the close and host a conference call at 1:30 p.m. PT on May 2.

7 months ago - Business Wire

Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will issue it's 1Q-2024 results after the close on May 2, 2024, and host a conference call to discuss results at 1:30 p.m. PDT.

8 months ago - Business Wire

Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

LOS ANGELES--(BUSINESS WIRE)--The FDA cleared Puma Biotechnology's IND for Alisertib in HER2-negative, hormone receptor-positive metastatic breast cancer.

9 months ago - Business Wire

Puma Biotechnology, Inc. (PBYI) Q4 2023 Earnings Call Transcript

Puma Biotechnology, Inc. (PBYI) Q4 2023 Earnings Call Transcript

9 months ago - Seeking Alpha

Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology released it's fourth quarter and full year 2023 earnings and will host a conference call to discuss operating results and outlook.

9 months ago - Business Wire

Puma Biotechnology to Participate in a Panel Discussion at TD Cowen's 44th Annual Health Care Conference

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology CEO and President Alan Auerbach will participate in a Breast & Lung Cancer panel on 3/6/24 at TD Cowen's Health Care Conference .

10 months ago - Business Wire

Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology will host a conference call at 1:30 p.m. PT on Feb. 29 to discuss its fourth quarter and full year 2023 earnings results.

10 months ago - Business Wire

Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced that it had initiated ALISCA-Lung1, a Phase II clinical trial of alisertib in small cell lung cancer.

10 months ago - Business Wire

Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference

LOS ANGELES--(BUSINESS WIRE)--Alan Auerbach, CEO and President of Puma Biotechnology, will present an update on Puma Biotechnology at the B. Riley Oncology Conf. on Jan. 18, 2024.

11 months ago - Business Wire

Puma Biotechnology: Profitable, Troubled, But Worth A Good Look

Puma Biotechnology is a commercial-stage biotech with a struggling approved drug, neratinib, but potential for gains. The company is focused on refining current indications for neratinib and investiga...

1 year ago - Seeking Alpha

Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced the design of the Phase 2 alisertib trial for treatment of HER2-, HR+ metastatic breast cancer (PUMA-ALI-1201).

1 year ago - Business Wire